Tell your friends about this item:
The Pharmagellan Guide to Biotech Forecasting and Valuation Frank S David
Ordered from remote warehouse
Our customers say:
The Pharmagellan Guide to Biotech Forecasting and Valuation
Frank S David
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser--or aspire to be one--then you need to know how to build and analyze forecasts and valuation models of R& D-stage drugs.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
- Vetted benchmarks for key drivers of income, expenses, and valuation.
- Proprietary analyses by Pharmagellan's experienced consulting team.
- More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R& D program, this is the one-stop guide you need by your side.
| Media | Books Paperback Book (Book with soft cover and glued back) |
| Released | January 6, 2017 |
| ISBN13 | 9780998407500 |
| Publishers | Pharmagellan, LLC |
| Pages | 138 |
| Dimensions | 152 × 229 × 8 mm · 213 g |
| Language | English |
